Evaluating the Feasibility of Using Neurosteer's Brain Activity Monitor in the Neurosciences Intensive Care Unit

What this Trial Is About

This research aims to assess the clinical usefulness of Neurosteer's brain monitoring platform for tracking delirium, sedation, and agitation in intubated and sedated patients in the Neurosciences Intensive Care Unit (NSICU). The study will enroll 100 patients admitted to the NSICU, half with Acute Neurological Injuries (ANI) such as strokes, brain injuries, or infections, and half without ANI but with other critical illnesses. Researchers will compare the Neurosteer device's signals with standard assessments like the Richmond Agitation-Sedation Scale (RASS), Confusion Assessment Method (CAM-ICU), and continuous EEG monitoring. All participants will receive the Neurosteer single-channel EEG monitoring device, which will be placed on their forehead for continuous monitoring during their NSICU stay. Auditory stimulation through earphones will be delivered 3-4 times daily alongside RASS assessments and 1-2 times daily with CAM-ICU assessments. The study will track correlations between Neurosteer readings and traditional measures of sedation and delirium. The intervention lasts for the entire NSICU admission, averaging around 14 days. Participants will be closely monitored with hourly RASS and CAM-ICU evaluations, continuous EEG for some, and Neurosteer device recordings. Data will be collected throughout their stay to analyze sedation depth and delirium presence. The study includes statistical analyses during and after enrollment. Informed consent will be obtained from patients or their representatives. Researchers will compare results within and between patient groups with and without ANI to evaluate the monitoring platform's performance.

Neurosteer Bedside Monitoring System